Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03221257 · ClinicalTrials.gov registry record · Phase 2
Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate
A Phase 2 study of Interstitial Lung Disease and Scleroderma, Systemic, sponsored by Michael Roth.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 16
- Study locations
NCT03221257 is a Phase 2 study of Interstitial Lung Disease and Scleroderma, Systemic that has completed, run by Michael Roth. The registered enrollment target is 51 participants, below the 565-participant average among 36 other Interstitial Lung Disease trials with a reported enrollment target (91% lower). The trial reports 16 study locations across 15 states.
The verdict
NCT03221257, a Phase 2 study of Interstitial Lung Disease and Scleroderma, Systemic, has completed, sponsored by Michael Roth.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 16
- Study locations
Study Summary
A Phase II multi-center, double-blind, parallel group, randomized and placebo-controlled clinical trial addressing the treatment of patients with active and symptomatic Scleroderma-related interstitial lung disease (SSc-ILD).
Conditions Studied
Interventions
- DRUG Mycophenolate Mofetil (MMF)
- DRUG Pirfenidone (PFD)
- DRUG Placebo (Plac)
Study Locations (16)
Massachusetts
- Harvard Medical School, Brigham & Women's Hospital - Boston
- Boston University, School of Medicine - Boston
California
- University of California Los Angeles - Los Angeles
Colorado
- University of Colorado - Aurora
District of Columbia
- Georgetown University - Washington D.C.
Illinois
- Northwestern University - Chicago
Indiana
- Indiana University Health - Indianapolis
Maryland
- Johns Hopkins University - Baltimore
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2017-11-28 |
| Est. Completion | 2022-06-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03221257
The ClinicalTrials.gov registry entry for NCT03221257 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 565-participant average among 36 other Interstitial Lung Disease trials with a reported enrollment target (91% lower). The listed sponsor is Michael Roth, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Interstitial Lung Disease appearing as the primary indexed condition, and to 3 interventions - of which Mycophenolate Mofetil (MMF) is the first listed.
NCT03221257 reports 16 study locations spanning 15 distinct geographic areas - top geographies include Massachusetts, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT03221257 about?
NCT03221257 is a clinical study titled "Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate". A Phase II multi-center, double-blind, parallel group, randomized and placebo-controlled clinical trial addressing the treatment of patients with active and symptomatic Scleroderma-related interstitial lung disease (SSc-ILD).
What is the current status of trial NCT03221257?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2017-11-28. Estimated completion is 2022-06-13.
What conditions does trial NCT03221257 study?
This clinical trial studies the following conditions: Interstitial Lung Disease, Scleroderma, Systemic.
What interventions are being tested in trial NCT03221257?
The interventions under investigation include: Mycophenolate Mofetil (MMF) (DRUG), Pirfenidone (PFD) (DRUG), Placebo (Plac) (DRUG).
Who is sponsoring clinical trial NCT03221257?
This trial is sponsored by Michael Roth, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03221257 being conducted?
This trial has 16 study locations across California, Colorado, District of Columbia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Interstitial Lung Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
RECRUITING · Phase 2
-
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
RECRUITING · Phase 2
-
A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
RECRUITING · Phase 2
-
129Xe MRI Cardiopulmonary
RECRUITING · Phase 2
-
Pulmonary Hypertension SOLAR
RECRUITING · Phase 2
-
H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.